{"slideshow_credits": null, "snippet": "The $66 billion acquisition by Actavis would be the largest deal this year and would thwart the takeover effort of Valeant and William A. Ackman.", "abstract": "The $66 billion acquisition by Actavis would be the largest deal this year and would thwart the takeover effort of Valeant and William A. Ackman.", "section_name": "Business Day", "print_page": null, "document_type": "blogpost", "byline": {"person": [{"firstname": "David", "role": "reported", "lastname": "GELLES", "rank": 1, "organization": ""}], "original": "By DAVID GELLES"}, "web_url": "http://dealbook.nytimes.com/2014/11/17/allergan-agrees-to-be-sold-to-actavis/", "lead_paragraph": null, "headline": {"main": "Allergan Escapes Valeant's Pursuit, Agreeing to Be Bought by Actavis", "print_headline": "Deal Thwarted BB a Company Newly Irish", "kicker": "DealBook"}, "_id": "546a083138f0d8317bec1f0a", "word_count": "1065", "multimedia": [{"height": 126, "url": "images/2014/11/18/business/Drugjp/Drugjp-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2014/11/18/business/Drugjp/Drugjp-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 401, "url": "images/2014/11/18/business/Drugjp/Drugjp-articleLarge.jpg", "legacy": {"xlarge": "images/2014/11/18/business/Drugjp/Drugjp-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "401"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2014/11/18/business/Drugjp/Drugjp-thumbStandard.jpg", "legacy": {"thumbnail": "images/2014/11/18/business/Drugjp/Drugjp-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2014-11-17T09:34:22Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Ackman, William A", "name": "persons", "rank": "1"}, {"value": "Pyott, David E I", "name": "persons", "rank": "2"}, {"value": "Actavis PLC", "name": "organizations", "rank": "1"}, {"value": "Allergan Inc", "name": "organizations", "rank": "2"}, {"value": "Pershing Square Capital Management", "name": "organizations", "rank": "3"}, {"value": "Valeant Pharmaceuticals International Inc", "name": "organizations", "rank": "4"}, {"value": "Corporate Taxes", "name": "subject", "rank": "1"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "2"}, {"value": "Mergers, Acquisitions and Divestitures", "name": "subject", "rank": "3"}], "blog": [], "subsection_name": "Dealbook", "type_of_material": "Blog"}